106 related articles for article (PubMed ID: 19944888)
1. The burden of depressive symptoms in people with schizophrenia.
Conley RR
Psychiatr Clin North Am; 2009 Dec; 32(4):853-61. PubMed ID: 19944888
[TBL] [Abstract][Full Text] [Related]
2. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.
Conley RR; Ascher-Svanum H; Zhu B; Faries DE; Kinon BJ
Schizophr Res; 2007 Feb; 90(1-3):186-97. PubMed ID: 17110087
[TBL] [Abstract][Full Text] [Related]
3. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand.
Maneesakorn S; Robson D; Gournay K; Gray R
J Clin Nurs; 2007 Jul; 16(7):1302-12. PubMed ID: 17584349
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance, evaluation, and management of secondary depression in schizophrenia.
Becker RE; Singh MM; Meisler N; Shillcutt S
J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):26-32. PubMed ID: 2865254
[TBL] [Abstract][Full Text] [Related]
5. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
Chue P
J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
7. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
[TBL] [Abstract][Full Text] [Related]
8. Relapse prevention and recovery in the treatment of schizophrenia.
Schooler NR
J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
[TBL] [Abstract][Full Text] [Related]
9. The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice.
Mahmoud R; Engelhart L; Ollendorf D; Oster G
J Clin Psychiatry; 1999; 60 Suppl 3():42-7; discussion 48. PubMed ID: 10073377
[TBL] [Abstract][Full Text] [Related]
10. [Depressive symptoms in schizophrenia].
Gerard A
Encephale; 1998 Jul; 24 Spec No 1():24-6. PubMed ID: 9809250
[No Abstract] [Full Text] [Related]
11. [Effect of neuroleptics on depressive symptoms].
Tabeze JP
Encephale; 1998 Jul; 24 Spec No 1():38-41. PubMed ID: 9809254
[No Abstract] [Full Text] [Related]
12. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.
Hofer A; Kemmler G; Eder U; Edlinger M; Hummer M; Fleischhacker WW
J Clin Psychiatry; 2004 Jul; 65(7):932-9. PubMed ID: 15291682
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostics and therapy of depressive symptoms in schizophrenic patients].
Bottlender R; Hampel H; Sievers M; Möller HJ
MMW Fortschr Med; 2005 May; 147 Spec No 2():59-62. PubMed ID: 15968875
[TBL] [Abstract][Full Text] [Related]
14. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
15. Bupropion for depression in schizophrenia.
Englisch S; Inta D; Eer A; Zink M
Clin Neuropharmacol; 2010; 33(5):257-9. PubMed ID: 20852411
[TBL] [Abstract][Full Text] [Related]
16. Substance abuse and the management of medication nonadherence in schizophrenia.
Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
[TBL] [Abstract][Full Text] [Related]
17. Symptoms of depression in schizophrenia.
Murali T; Ravi Kumar S
Indian J Med Res; 2008 Jun; 127(6):516-8. PubMed ID: 18765867
[No Abstract] [Full Text] [Related]
18. [Prevalence of depressive symptoms in a population of ambulatory schizophrenics].
Lempérière T; Rodière C; Rousselet N; Pilate C; Ades J; Lépine JP; Rouillon F
Ann Med Psychol (Paris); 1983 Feb; 141(2):224-36. PubMed ID: 6137178
[No Abstract] [Full Text] [Related]
19. [Therapeutic alliance, a stake in schizophrenia].
Charpentier A; Goudemand M; Thomas P
Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
[TBL] [Abstract][Full Text] [Related]
20. Quality of life measurement in mental health. Introduction and overview of workshop findings.
Holley H
Can J Commun Ment Health; 1998; (3 Suppl):9-20, 9-21. PubMed ID: 10344890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
